Abstracts Archive - Page 688 of 2607 - ACR Meeting Abstracts

Abstract Number: PP11 • ACR Convergence 2022
Exercise as a Supportive Treatment for My Ankylosing Spondylitis
Sara King-Dowling, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are often caught in a paradox as they experience mobility challenges, but long periods of immobility cause increased…
Abstract Number: PP10 • ACR Convergence 2022
How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
Brooklyn Johnson¹ and Kathleen Collins², ¹Memphis, TN, ²LeBonheur Children's Hospital, Memphis, TN
Background/Purpose: The summer before my senior year, I developed a faint rash on my face and my arms. At a dermatology appointment, I pointed this…
Abstract Number: PP12 • ACR Convergence 2022
We Became Advocates, Educators, and a Support System for Hispanic/Latino Patients with Rheumatoid Arthritis and Their Caregivers Through Involvement in a Virtual Patient Advisory Board
Zucy Almonacid¹, Wigna Cruz², Francisca Garcia³, Teresa Hernandez⁴, Velia Martinez⁵, Patricia Mattos³, Mario Mutis⁶ and Denise Serrano⁷, ¹Hicsville, NY, ²Juan Diaz, PR, ³Lake Worth, FL, ⁴Greenacres, FL, ⁵Guaynabo, PR, ⁶Fort Pierce, FL, ⁷Toa Alto, PR
Background/Purpose: Each of us has been diagnosed with rheumatoid arthritis (RA), from as recently as one year ago to as long as 20 years ago.…
Abstract Number: PP09 • ACR Convergence 2022
A Matter of Life and Death: Why Diversity, Equity and Inclusion Matter for Health Care Providers
Tonya Horton, Rutgers University, Cherry Hill, NJ
Background/Purpose: In 2017, I went from exercising daily to hardly able to walk due to severe knee pain. My primary care doctor ordered x-rays and…
Abstract Number: 2265 • ACR Convergence 2022
Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus
Henri Tiedge¹, ILHAM MUSLIMOV², Valerio Berardi², Stacy Stephenson³, Ellen M. Ginzler⁴, Anca Askanase⁵ and John Hanly⁶, ¹SUNY, Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, NY, ³SUNY Downstate Medical Center, dep. of Comparative Medicine, Brooklyn, NY, ⁴SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) involvement is common in systemic lupus erythematosus (SLE). Manifestations often include seizures and cognitive impairment but underlying etiology remains poorly understood. Brain…
Abstract Number: PP16 • ACR Convergence 2022
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
Ashley Krivohlavek, Oklahoma City, OK
Background/Purpose: At age 12, I was diagnosed with psoriasis (PsO) followed by a diagnosis of psoriatic arthritis (PsA) at age 30. I'm now 38. In…
Abstract Number: PP20 • ACR Convergence 2022
‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease
Melissa Allman, Michigan State University, Meridian Charter Township, MI
Background/Purpose: Trauma can have profound detrimental influences on our health and well-being. I am tangibly familiar with how trauma can impact the individual due to…
Abstract Number: PP18 • ACR Convergence 2022
From Devastated to Empowered: How Patient Engagement in Research Changes Lives
Eileen Davidson, Burnaby, BC, Canada
Background/Purpose: In April of 2015 I was a 29 year-old single mom diagnosed with rheumatoid arthritis (RA). RA wasn't unknown to me; my aunt who…
Abstract Number: PP23 • ACR Convergence 2022
The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY
Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
Abstract Number: PP22 • ACR Convergence 2022
Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance
Natasha Trehan¹ and Laurie Proulx², ¹Take a Pain Check Foundation, Markham, ON, Canada, ²Canadian Arthritis Patient Alliance, Ottawa, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis is a chronic disease that affects a child's school life and relationships, creating social isolation for youth and young adults. Take…
Abstract Number: PP25 • ACR Convergence 2022
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
Shung Chiu¹ and Mei Nee Chiu², ¹Spondylitis Association of America, Ludhiana, Punjab, India, ²University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India
Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
Abstract Number: PP24 • ACR Convergence 2022
Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp
Kaye Anderson¹, Kristine Carandang² and Courtney Wells³, ¹Young Patients' Autoimmune Research & Empowerment Alliance, River Falls, WI, ²Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ³University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN
Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of ten. The constant battle between doctor appointments, pain, and medication side effects left…
Abstract Number: PP14 • ACR Convergence 2022
The Use of Social Support as Treatment
Aleta McLean, Open Hand Atlanta, Atlanta, GA
Background/Purpose: The months leading up to my diagnosis were frustrating. Initially my hair started falling out. I was told it was stress related. I was…
Abstract Number: 2268 • ACR Convergence 2022
Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cecile Yelnik¹, Zeynep Belce Erton², Elodie Drumez³, Dachi Cheildze², Danieli Castro Oliveira de Andrade⁴, Ann E Clarke⁵, Maria G. Tektonidou⁶, Vittorio Pengo⁷, Savino Sciascia⁸, Amaia Ugarte⁹, H Michael Belmont¹⁰, Mª Angeles Aguirre¹¹, Paul fortin¹², maria gerosa¹³, Flavio Victor Signorelli¹⁴, Tatsuya Atsumi¹⁵, Zhouli Zhang¹⁶, Hannah Cohen¹⁷, D. Ware Branch¹⁸, Denis Wahl¹⁹, Laura Andreoli²⁰, Esther Rodriguez Almaraz²¹, Michelle Petri²², Ricard Cervera²³, Yu Zuo²⁴, Bahar Artim-Esen²⁵, Guillermo Pons-Estel²⁶, Rohan Willis²⁷, Maria Laura Bertolaccini²⁸, Robert Roubey²⁹, Doruk Erkan² and on behalf of APS ACTION On Behalf Of APS ACTION², ¹Lille University, Lille, France, ²Hospital for Special Surgery, New York, NY, ³Université de Lille, Lille, France, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁶National and Kapodistrian University of Athens, Athens, Greece, ⁷Padova University Hospital, Padova, Italy, ⁸University of Turin, Torino, Italy, ⁹BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, ¹⁰NYU School of Medicine, New York, NY, ¹¹Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹²CHU de Québec, Pavillon CHUL, Québec, Canada, ¹³University of Milan, Milano, Italy, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁵Hokkaido University, Sapporo, Japan, ¹⁶Peking University First Hospital, Beijing, China, ¹⁷University College London, London, United Kingdom, ¹⁸University of Utah, Salt Lake City, UT, ¹⁹Université de Nancy, Nancy, France, ²⁰Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²³Hospital Clínic de Barcelona, Barcelona, Spain, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Istanbul University, Istanbul, Turkey, ²⁶CREAR, Rosario, Argentina, ²⁷University of Texas Medical Branch, Galveston, TX, ²⁸King's College London, London, United Kingdom, ²⁹University of North Carolina, Chapel Hill, NC
Background/Purpose: Long-term anticoagulation is the standard of care for antiphospholipid syndrome (APS) patients with macrovascular thrombosis. However, in daily practice, long-term anticoagulation may not be…
Abstract Number: 2168 • ACR Convergence 2022
A Novel Pharmaco-Interventional Approach for the Treatment of Refractory Digital Ischemia in Systemic Sclerosis – Percutaneous Revascularization Combined with Intravenous Vasodilatory Therapy
Lily Romero Karam¹, Kevin Honan¹, Salman Arain¹ and Maureen Mayes², ¹University of Texas Health Science Center at Houston, Houston, TX, ²Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: The combination of Raynaud´s Phenomenon (RP) and vasculopathy, characterized by intimal proliferation and fibrosis, endothelial dysfunction, and smooth-muscle activation, can lead to severe digital…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].